Entero Therapeutics Inc.
13F holders, Q3 2024 (September 30)10holders +2
4new positions
2sold out
1famous investor
$0.34avg. 13F price*
At the end of Q3 2024, 10 institutions reported holding Entero Therapeutics Inc. in their 13F filings, up 2 from Q2 2024. 4 opened new positions and 2 sold out. The largest holders were Virtu Financial LLC ($11K), Two Sigma Securities, LLC ($9K) and Geode Capital Management, LLC ($6K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Entero Therapeutics Inc.
- CUSIP
- 33749P408
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $24K |
| Exits | 2 | $155K |
All 13F filers, Q2 2024 → Q3 2024: 71,826 shares bought and 126,540 shares sold, net −54,714 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Virtu Financial LLC | 0.00% | New | 32,190 | $11K |
| Two Sigma Securities, LLC | 0.00% | New | 26,612 | $9K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.6% | 16,055 | $6K |
| Citadel Advisors | 0.00% | New | 10,052 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +36.5% | 7,484 | $3K |
| FMR LLC | 0.00% | New | 965 | $332 |
| Bank of America Corp. | 0.00% | Add +18.2% | 26 | $9 |
| US Bancorp \de | 0.00% | No change | 1 | $0 |
| UBS Group AG | 0.00% | Reduce -99.8% | 1 | $0 |
| Kathleen S. Wright Associates Inc. | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is ENTERO THERAPEUTICS INC's weight in each manager's 13F, not the share of Entero Therapeutics Inc. the manager owns.